Febuxostat
Febuxostat
复制标题
DOI：
10.1038/nrd2831
复制
发表时间：
2009-03-01
影响因子：
120.1
通讯作者：
Kirkpatrick, Peter
中科院分区：
文献类型：
--
作者：
Pascual, Eliseo;Sivera, Francisca;Kirkpatrick, Peter
2008年5月，黄嘌呤氧化酶抑制剂非布司他（Adenuric; Ipsen）获得欧盟委员会的上市许可，用于治疗发生尿酸盐沉积的慢性高尿酸血症，例如痛风性关节炎。
In May 2008, febuxostat (Adenuric; Ipsen), an inhibitor of xanthine oxidase, was granted marketing authorization by the European Commission for the treatment of chronic hyperuricaemia in conditions in which urate deposition has occurred, such as gouty arthritis.